Pharma AI glossary

Shadow AI

Employees using personal, unsanctioned AI tools for work: pasting company content into consumer chatbots.

Employees using personal, unsanctioned AI tools for work: pasting company content into consumer chatbots. MIT's 2025 research: >90% of companies have it while <50% provide sanctioned alternatives. Twin risks: confidential data leaving controlled environments, and work product entering records with zero governance. The effective response is economic, not just prohibitive: provide an approved tool good enough that the shadow one loses (Merck's GPTeal, Moderna's mChat), then draw bright data lines and train to them.

Demand ahead of governance

Shadow AI is employees using unapproved tools (public LLMs, personal copilots, browser extensions) outside your governed agent harness for work tasks. Adoption often outpaces formal rollout on manufacturing floors, in QC labs, and in QA inboxes. The operational risk is confidential data leaving approved boundaries, drafts with no audit trail, and outputs entering batch records, CAPA, or QMS without workflow controls.

Literacy response

Policies that rely on bans alone rarely work. Channel the demand with approved tools, clear allowed use cases, Article 4-style training, and a culture where staff can report mistakes. Literacy programs should name shadow AI explicitly and offer safer alternatives so assessments reflect real practice.

Frequently asked questions

How do we detect shadow AI?

Combine DLP signals, access logs, culture surveys, and review of where drafts originate, then address the unmet need driving users to unsanctioned tools.

Is shadow AI a cybersecurity or quality issue?

Both. CISO and QA should co-own policy: confidentiality, integrity, and validated state all break when outputs enter manufacturing or quality records undocumented, whether from investigations, batch review, or CAPA work.

What approved alternatives should we offer?

Governed agents or applications for the jobs staff are already doing informally: SOP search, investigation and CAPA drafting, batch record summarization, and training Q&A, each with enterprise access control, logging, and human release gates.

Benchmark your AI literacy

Free 20-question assessment, eight modules, and instant scoring, built for pharma quality and manufacturing teams.

Open the Literacy Center

Browse all terms

See the full 71-term glossary index or search interactively in the Literacy Center.

Back to glossary hub →

Educational content only, not legal or regulatory advice. Regulatory guidance cited here includes drafts (FDA AI credibility guidance; EU GMP Annex 22) as of August 2026; verify against final texts before relying on them in submissions. Company-reported figures (Merck CSR timings, Sanofi results) are labeled where used. MIT's ~95% pilot figure carries its own caveat (~150 interviews, contested definitions, not peer-reviewed). Re-check sources on module finalization.

Definition